Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.06 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.05 per share when it actually produced a loss of $0.09, delivering a surprise of -80%.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.Stereotaxis, which belongs to the Zack ...

Power Integrations (POWI) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.71%. A quarter ago, it was expected that this maker of integrated circuits used for power conversion would post earnings of $0.27 per share when it actually produced earnings of $0.30, delivering a surprise o ...

分组1 - Arcturus Therapeutics reported a quarterly loss of $0.52 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.58, representing an earnings surprise of 67.09% [1] - The company posted revenues of $29.38 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 3.10%, but down from $38.01 million year-over-year [2] - Over the last four quarters, Arcturus has surpassed consensus EPS estimates three times and topped revenue estimates twice [2] 分组2 - The stock has underperformed, losing about 35.3% since the beginning of the year, compared to a decline of 3.8% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$1.77 on revenues of $21.84 million, and for the current fiscal year, it is -$6.44 on revenues of $96.5 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Company Performance - Cue Biopharma reported a quarterly loss of $0.17 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.14, representing an earnings surprise of -21.43% [1] - The company posted revenues of $0.42 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 78.95%, compared to revenues of $1.72 million a year ago [2] - Over the last four quarters, Cue Biopharma has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Movement and Outlook - Cue Biopharma shares have declined approximately 28.5% since the beginning of the year, while the S&P 500 has only declined by 3.8% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.14 on $2 million in revenues, and -$0.58 on $8.36 million in revenues for the current fiscal year [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Cue Biopharma belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The Zacks Rank for Cue Biopharma is currently 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6]

Core Insights - Dianthus Therapeutics, Inc. reported a quarterly loss of $0.82 per share, which was better than the Zacks Consensus Estimate of a loss of $0.86, but worse than the loss of $0.54 per share from the previous year, indicating a 51.85% increase in loss year-over-year [1] - The company achieved revenues of $1.16 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.13% and showing a 33.33% increase from $0.87 million in the same quarter last year [2] - The stock has underperformed the market, losing approximately 10.1% since the beginning of the year compared to the S&P 500's decline of 3.8% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.93 on revenues of $1.36 million, while for the current fiscal year, the estimate is -$3.38 on revenues of $5.17 million [7] - The estimate revisions trend for Dianthus Therapeutics is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Dianthus Therapeutics belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Group 1 - Enanta Pharmaceuticals reported a quarterly loss of $1.06 per share, slightly worse than the Zacks Consensus Estimate of a loss of $1.04, but an improvement from a loss of $1.47 per share a year ago, indicating an earnings surprise of -1.92% [1] - The company posted revenues of $14.93 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 8.71%, and down from $17.05 million in the same quarter last year [2] - Enanta Pharmaceuticals shares have declined approximately 8.4% since the beginning of the year, compared to a decline of 3.8% for the S&P 500 [3] Group 2 - The earnings outlook for Enanta Pharmaceuticals is mixed, with the current consensus EPS estimate for the upcoming quarter at -$1.15 on revenues of $16.34 million, and for the current fiscal year at -$3.90 on revenues of $64.44 million [7] - The Zacks Industry Rank for Medical - Drugs is currently in the top 27% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8] - Plus Therapeutics, another company in the same industry, is expected to report a quarterly loss of $0.17 per share, reflecting a year-over-year change of +77.3%, with revenues projected to be $1.85 million, up 10.1% from the previous year [9]

Company Performance - Quest Resource reported a quarterly loss of $0.14 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.05, and compared to a loss of $0.03 per share a year ago, indicating a significant earnings surprise of -180% [1] - The company posted revenues of $68.43 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 5.63%, and down from $72.65 million in the same quarter last year [2] - Over the last four quarters, Quest Resource has not surpassed consensus EPS or revenue estimates [2] Stock Performance - Quest Resource shares have declined approximately 61.7% since the beginning of the year, contrasting with the S&P 500's decline of -3.8% [3] - The current Zacks Rank for Quest Resource is 5 (Strong Sell), indicating expectations for the stock to underperform the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.06 on revenues of $75.84 million, and for the current fiscal year, it is $0.21 on revenues of $304.77 million [7] - The trend for estimate revisions ahead of the earnings release has been unfavorable, which could impact future stock performance [6] Industry Context - The Waste Removal Services industry, to which Quest Resource belongs, is currently ranked in the bottom 30% of over 250 Zacks industries, suggesting a challenging environment for the company [8]

Group 1 - Clipper Realty Inc. reported quarterly funds from operations (FFO) of $0.19 per share, exceeding the Zacks Consensus Estimate of $0.16 per share, and up from $0.14 per share a year ago, representing an FFO surprise of 18.75% [1] - The company posted revenues of $39.4 million for the quarter ended March 2025, which missed the Zacks Consensus Estimate by 2.48%, compared to year-ago revenues of $35.76 million [2] - Clipper Realty has surpassed consensus FFO estimates in all four of the last quarters, while it has only topped consensus revenue estimates once in the same period [2] Group 2 - The stock has underperformed the market, losing about 12.5% since the beginning of the year, compared to the S&P 500's decline of 3.8% [3] - The current consensus FFO estimate for the coming quarter is $0.13 on revenues of $41.9 million, and for the current fiscal year, it is $0.47 on revenues of $162.6 million [7] - The Zacks Industry Rank for REIT and Equity Trust - Other is currently in the bottom 41% of over 250 Zacks industries, indicating potential challenges for the sector [8]

Financial Performance - Quanterix Corporation reported a quarterly loss of $0.53 per share, better than the Zacks Consensus Estimate of a loss of $0.69, but worse than a loss of $0.26 per share a year ago, indicating an earnings surprise of 23.19% [1] - The company posted revenues of $30.33 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 8.99%, although this is a decline from year-ago revenues of $32.07 million [2] - Over the last four quarters, Quanterix has surpassed consensus revenue estimates three times [2] Stock Performance - Quanterix shares have declined approximately 50.3% since the beginning of the year, compared to a decline of 3.8% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of $30.83 million, and for the current fiscal year, it is -$1.62 on revenues of $138.32 million [7] Industry Outlook - The Medical - Products industry, to which Quanterix belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Quanterix's stock performance [5]

Core Viewpoint - Geron Corporation is facing a class action lawsuit due to alleged misleading statements regarding its revenue outlook and the market potential of its drug Rytelo, leading to significant stock price decline after disappointing financial results were announced [3][4]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased Geron securities between February 28, 2024, and February 25, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations Against Geron - The lawsuit claims that Geron misrepresented its revenue projections and growth potential, downplaying risks related to seasonality and macroeconomic conditions [3]. - It is alleged that Geron's optimistic portrayal of Rytelo's launch was overstated, with actual market conditions affecting patient uptake more than indicated [3]. - The company failed to achieve significant market penetration for Rytelo, particularly among first-line patients, due to limited awareness and competitive pressures [3]. Group 3: Financial Impact - On February 26, 2025, Geron reported stagnant growth for Rytelo, attributing this to seasonality, competition, and monitoring burdens, which led to a stock price drop of over 32% [4].